Weight gain and integrase inhibitors
AR Eckard, GA McComsey - Current opinion in infectious diseases, 2020 - journals.lww.com
Although INSTI-based regimens are highly efficacious for viral suppression, they appear to
cause more weight gain and treatment emergent obesity than non-INSTI-based regimens …
cause more weight gain and treatment emergent obesity than non-INSTI-based regimens …
Antiretroviral therapy: current drugs
AK Pau, JM George - Infectious Disease Clinics, 2014 - id.theclinics.com
The 1980s saw the devastation of the newly emerging and deadly disease of acquired
immunodeficiency syndrome (AIDS). The identification of the retrovirus, now known as …
immunodeficiency syndrome (AIDS). The identification of the retrovirus, now known as …
Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non …
P Cahn, AL Pozniak, H Mingrone, A Shuldyakov… - The Lancet, 2013 - thelancet.com
Summary Background Dolutegravir (GSK1349572), a once-daily HIV integrase inhibitor, has
shown potent antiviral response and a favourable safety profile. We evaluated safety …
shown potent antiviral response and a favourable safety profile. We evaluated safety …
HIV-1 integrase inhibitors: a comparative review of efficacy and safety
KK Scarsi, JP Havens, AT Podany, SN Avedissian… - Drugs, 2020 - Springer
The newest class of antiretrovirals for all persons living with HIV are the integrase strand
transfer inhibitors (INSTIs). Since 2007, five INSTIs have been introduced: raltegravir …
transfer inhibitors (INSTIs). Since 2007, five INSTIs have been introduced: raltegravir …
Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double …
F Raffi, H Jaeger, E Quiros-Roldan… - The Lancet infectious …, 2013 - thelancet.com
Background In the primary analysis of SPRING-2 at week 48, dolutegravir showed non-
inferior efficacy to and similar tolerability to raltegravir in adults infected with HIV-1 and naive …
inferior efficacy to and similar tolerability to raltegravir in adults infected with HIV-1 and naive …
Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society–USA panel
MA Thompson, JA Aberg, P Cahn, JSG Montaner… - Jama, 2010 - jamanetwork.com
Context Recent data regarding the consequences of untreated human immunodeficiency
virus (HIV) infection and the expansion of treatment choices for antiretroviral-naive and …
virus (HIV) infection and the expansion of treatment choices for antiretroviral-naive and …
Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis
Background New antiretroviral therapy (ART) regimens for HIV could improve clinical
outcomes for patients. To inform global guidelines, we aimed to assess the comparative …
outcomes for patients. To inform global guidelines, we aimed to assess the comparative …
Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label …
JM Molina, B Clotet, J van Lunzen, A Lazzarin… - The lancet HIV, 2015 - thelancet.com
Background The primary analysis of the FLAMINGO study at 48 weeks showed that patients
taking dolutegravir once daily had a significantly higher virological response rate than did …
taking dolutegravir once daily had a significantly higher virological response rate than did …
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and …
E DeJesus, JK Rockstroh, K Henry, JM Molina, J Gathe… - The Lancet, 2012 - thelancet.com
Background The HIV integrase strand transfer inhibitor elvitegravir (EVG) has been co-
formulated with the CYP3A4 inhibitor cobicistat (COBI), emtricitabine (FTC), and tenofovir …
formulated with the CYP3A4 inhibitor cobicistat (COBI), emtricitabine (FTC), and tenofovir …
Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose …
J van Lunzen, F Maggiolo, JR Arribas… - The Lancet infectious …, 2012 - thelancet.com
Summary Background Dolutegravir (S/GSK1349572) is a new HIV-1 integrase inhibitor that
has antiviral activity with once daily, unboosted dosing. SPRING-1 is an ongoing study …
has antiviral activity with once daily, unboosted dosing. SPRING-1 is an ongoing study …